Jefferies reiterated its Buy rating and $6 price target on Dynavax Technologies (NASDAQ: DVAX) following yesterday's FDA briefing documents Heplisav.
This article: 104 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE